Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Mupirocin (formerly BRL-4910A; BRL 4910A; Pseudomonic acid; Mupirocin, Bactroban, Centany) is a potent and orally bioactive isoleucyl t-RNA synthetase inhibitor and a naturally occuring antibiotic isolated from Pseudomonas fluorescens. It is authorized for use in the management of skin infections caused by bacteria. One member of the monoxycarbolic acid class of antibiotics is mupirocin. Mupirocin has concentration-dependent effects; at low concentrations, it has bacteriostatic effects, while at high concentrations, it has bactericidal effects. It works well as a topical antibiotic against MRSA and other Gram-positive bacteria. More than 90% of the mixture in mupirocin is made up of pseudomonic acid A (PA-A), one of several pseudomonic acids that are present in the mixture.
Targets |
isoleucyl t-RNA synthetase
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
Cell Line: Staphylococcus aureus
Concentration: 0-100 μM/mL Incubation Time: 24, 48 hours Result: Resulted in a 90 to 99% reduction at 24 h, with MIC values ranged from 0.12-1.0 μM/mL and MBC values ranged from 4.0-32 μM/mL at 48 h. |
|
Animal Protocol |
MRSA skin infection model in mice (10-12 weeks old)
2% ointment External administration; twice daily; 3-6 days |
|
References |
|
Molecular Formula |
C26H44O9
|
|
---|---|---|
Molecular Weight |
500.62
|
|
Exact Mass |
500.3
|
|
Elemental Analysis |
C, 62.38; H, 8.86; O, 28.76
|
|
CAS # |
12650-69-0
|
|
Appearance |
Solid powder
|
|
SMILES |
C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O
|
|
InChi Key |
MINDHVHHQZYEEK-HBBNESRFSA-N
|
|
InChi Code |
InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
|
|
Chemical Name |
9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9975 mL | 9.9876 mL | 19.9752 mL | |
5 mM | 0.3995 mL | 1.9975 mL | 3.9950 mL | |
10 mM | 0.1998 mL | 0.9988 mL | 1.9975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03140423 | Active Recruiting |
Drug: Arm 1. Routine Care (Mupirocin/CHG) Drug: Arm 2. Iodophor/CHG Decolonization |
Staphylococcus Aureus | Harvard Pilgrim Health Care | May 1, 2017 | Phase 4 |
NCT02967432 | Completed | Drug: Mupirocin Topical Ointment Drug: Petroleum Jelly |
Staphylococcus | Crouse Hospital | October 2016 | Phase 2 |
NCT04287777 | Completed | Drug: Mupirocin gel Drug: Placebo |
Impetigo | Reig Jofre Group | February 2014 | Phase 3 |
NCT01949935 | Completed | Drug: Mupirocin | Surgical Site Infections | Horizon Health Network | March 2009 | Phase 3 |
NCT00156377 | Completed | Drug: Mupirocin | Staphylococcal Infections Cross Infection |
University Hospital Muenster | November 2002 | Phase 4 |
Histopathology of murine pressure ulcers infected with MRSA and given vehicle control or topical mupirocin treatment. Sci Rep . 2021 May 25;11(1):10935. td> |